Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
14.49
-0.53 (-3.53%)
At close: Jun 18, 2026, 4:00 PM EDT
14.30
-0.19 (-1.31%)
After-hours: Jun 18, 2026, 4:34 PM EDT
Vor Biopharma Employees
Vor Biopharma had 76 employees as of December 31, 2025. The number of employees decreased by 83 or -52.20% compared to the previous year.
Employees
76
Change
-83
Growth
-52.20%
Revenue / Employee
n/a
Profits / Employee
-$11,619,474
Market Cap
785.15M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 76 | -83 | -52.20% |
| Sep 30, 2025 | 154 | -5 | -3.14% |
| Jun 30, 2025 | 154 | - | - |
| Dec 31, 2024 | 159 | -9 | -5.36% |
| Dec 31, 2023 | 168 | 35 | 26.32% |
| Dec 31, 2022 | 133 | -2 | -1.48% |
| Dec 31, 2021 | 135 | 47 | 53.41% |
| Sep 30, 2021 | 122 | 52 | 74.29% |
| Jun 30, 2021 | 109 | 39 | 55.71% |
| Mar 31, 2021 | 92 | 22 | 31.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Phathom Pharmaceuticals | 371 |
| Geron | 258 |
| Olema Pharmaceuticals | 137 |
| Annexon | 93 |
| Inventiva | 77 |
| Alto Neuroscience | 68 |
| Zevra Therapeutics | 61 |
VOR News
- 10 days ago - Vor Bio announces China NMPA approval for telitacicept - TheFly
- 10 days ago - Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China - GlobeNewsWire
- 10 days ago - Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China - GlobeNewsWire
- 15 days ago - Vor Biopharma Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 17 days ago - Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 21 days ago - Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Vor Bio price target raised to $18 from $15 at Wedbush - TheFly
- 5 weeks ago - Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine - GlobeNewsWire